 |
|
|
| |
C-EDGE CO-STAR: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons Who Inject Drugs Receiving Opioid Agonist Therapy
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Jean Marie Arduino*1, Oren Shibolet2, Alain H. Litwin3, Jason Grebeley4, Frederick Altice5, Chizoba Nwankwo1, T. Christopher Mast1, Zhiwei Jiang1, Isaias N. Gendrano1, Heather L. Platt1, Gregory J. Dore4
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Tel-Aviv Medical Center and Tel-Aviv University, Tel-Aviv, Israel; 3Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA; 4The Kirby Institute, UNSW, Sydney, Australia; 5Yale School of Medicine, New Haven, CT, USA
|
| |
|
|
|
|
|
